Alternatively, up-regulation of miR-222 is also known to confer Tamoxifen drug-resistance in breast cancer cells through the negative regulation of ERα and cell cycle inhibitor p27Kip1 [21], [22]. This evidence concerns the gene CDKN1B and breast cancer.